Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.41 |
| ▸ | RAB9A | P51151 | 10/20 | 0.41 |
| ▸ | NPC1 | O15118 | 8/20 | 0.41 |
| ▸ | MAPT | P10636 | 8/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 6/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.39 |
| ▸ | RELA | Q04206 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20383528 | 0.85 | HPGD (0.45) | HPGDSMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL31520544 | 0.77 | GAA (0.35) | POLBGAA | |
| SCHEMBL13860388 | 0.77 | LMNA (0.44) | HPGDSMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL13975147 | 0.76 | SMN1; SMN2 (0.53) | HPGDSMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL1576525 | 0.75 | LMNA (0.47) | HPGDSMN1; SMN2RAB9AMAPTTDP1 | |
| SCHEMBL20217910 | 0.74 | NPC1 (0.37) | HPGDSMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL13861547 | 0.74 | NTRK1 (0.40) | RAB9AMAPTALDH1A1L3MBTL1HTT | |
| SCHEMBL25546330 | 0.74 | NPSR1 (0.47) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL15716170 | 0.74 | SMN1; SMN2 (0.47) | HPGDSMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL28240024 | 0.73 | HPGD (0.51) | HPGDSMN1; SMN2RAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246955-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2024-07-25 | — | — | US | disclosed |
| EP-4089087-B1 | METHOD FOR PREPARING PYRROLIDINYL UREA DERIVATIVE | ZHANGZHOU PIEN TZE HUANG PHARM (CN) | 2024-07-03 | — | — | EP | disclosed |
| CN-117836289-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use thereof | 上海睿跃生物科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4323353-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2024-02-21 | — | — | EP | disclosed |
| US-11708357-B2 | Crystal form of pyrrolidinyl urea derivative and application thereof | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2023-07-25 | — | — | US | disclosed |
| US-11691965-B2 | Method for preparing pyrrolidinyl urea derivative | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| CN-109970614-B | Compounds as TRKA kinase inhibitors and uses thereof | 阵列生物制药公司（US） | 2023-01-13 | — | — | CN | disclosed |
| WO-2022218289-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2022-10-20 | — | — | WO | disclosed |
| EP-3412663-B1 | NITROGEN-CONTAINING HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021139795-A1 | METHOD FOR PREPARING PYRROLIDINYL UREA DERIVATIVE | 漳州片仔癀药业股份有限公司 | 2021-07-15 | — | — | WO | disclosed |
| WO-2014078417-A1 | PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078417-A1 | PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078331-A1 | N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078454-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078331-A1 | N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078323-A1 | N-PYRROLIDINYL, N'-PYRAZOLYL- UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078323-A1 | N-PYRROLIDINYL, N'-PYRAZOLYL- UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078322-A1 | THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078322-A1 | THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2012158413-A2 | PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708357-B2 | Crystal form of pyrrolidinyl urea derivative and application thereof | NGF, LCK, RET | HPGD 3543/4885SMN1; SMN2 2671/4885RAB9A 1891/4885 |
| US-20240246955-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, NTRK1, NTRK3 | HPGD 1793/4885SMN1; SMN2 689/4885RAB9A 3109/4885 |
| US-11691965-B2 | Method for preparing pyrrolidinyl urea derivative | NGF, ULK2, KIT | HPGD 2034/4885SMN1; SMN2 3393/4885RAB9A 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.